RenovoRx, Inc. (Nasdaq: RNXT) announced the appointment of Richard A. Stark to its Board of Directors, effective November 18, 2026. The company also increased the size of its Board from six to seven directors to accommodate the new member.
Mr. Stark brings over 30 years of executive leadership experience in the medical technology industry. He currently serves as the Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing radiofrequency ablation technologies. Previously, he served as Chief Executive Officer, President, and a member of the board of directors of Sanarus Technologies from January 2018 to January 2021, where he led the company through its strategic transfer of technology assets to Hologic, Inc. He also held senior commercial leadership positions at AngioDynamics and RITA Medical Systems.
Mr. Stark has been an advisor to RenovoRx since December 5, 2024, providing strategic commercial advisory services. In connection with his appointment, the company awarded him 128,824 options to purchase shares of common stock with a grant date fair value of $120,000. These options have an exercise price of $1.12 per share and a term of ten years, vesting monthly over three years, with a full acceleration upon a change in control. Additionally, he will receive an annual cash retainer of $40,000 and is eligible for additional committee fees. He will also be granted an additional option award with a grant date fair value of $70,000 on October 1, 2027.
RenovoRx is a life sciences company commercializing RenovoCath, a patented, FDA-cleared drug-delivery device. The company is also evaluating intra-arterial gemcitabine delivered via RenovoCath as a novel drug-device product candidate for locally advanced pancreatic cancer. The company completed enrollment in the Phase III TIGeR-PaC clinical trial in August 2026 and anticipates initial topline data in the second half of 2027.